- Home
- BRY vs AMRN Comparison
BRY vs AMRN Comparison
Compare BRY & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRY
- AMRN
- Stock Information
- Founded
- BRY 1909
- AMRN 1989
- Country
- BRY United States
- AMRN Ireland
- Employees
- BRY N/A
- AMRN N/A
- Industry
- BRY Oil & Gas Production
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- BRY Energy
- AMRN Health Care
- Exchange
- BRY Nasdaq
- AMRN Nasdaq
- Market Cap
- BRY 186.1M
- AMRN 216.0M
- IPO Year
- BRY N/A
- AMRN 1993
- Fundamental
- Price
- BRY $2.84
- AMRN $15.65
- Analyst Decision
- BRY Buy
- AMRN Strong Sell
- Analyst Count
- BRY 2
- AMRN 1
- Target Price
- BRY $4.00
- AMRN $12.00
- AVG Volume (30 Days)
- BRY 781.3K
- AMRN 65.9K
- Earning Date
- BRY 08-06-2025
- AMRN 07-30-2025
- Dividend Yield
- BRY 4.20%
- AMRN N/A
- EPS Growth
- BRY N/A
- AMRN N/A
- EPS
- BRY 0.07
- AMRN N/A
- Revenue
- BRY $701,914,000.00
- AMRN $219,361,000.00
- Revenue This Year
- BRY N/A
- AMRN N/A
- Revenue Next Year
- BRY $0.91
- AMRN N/A
- P/E Ratio
- BRY $43.90
- AMRN N/A
- Revenue Growth
- BRY N/A
- AMRN N/A
- 52 Week Low
- BRY $2.11
- AMRN $7.08
- 52 Week High
- BRY $6.65
- AMRN $17.49
- Technical
- Relative Strength Index (RSI)
- BRY 43.96
- AMRN 57.86
- Support Level
- BRY $2.72
- AMRN $14.57
- Resistance Level
- BRY $2.93
- AMRN $15.25
- Average True Range (ATR)
- BRY 0.13
- AMRN 0.63
- MACD
- BRY -0.02
- AMRN -0.01
- Stochastic Oscillator
- BRY 19.35
- AMRN 94.67
About BRY Berry Corporation (bry)
Berry Corp (bry) is a western United States independent upstream energy company with a focus on the conventional, long-lived oil reserves in the San Joaquin basin of California. Its operating segments includes Exploration and Production (E&P) and Well Servicing and Abandonment. The company generates maximum revenue from the Exploration and Production (E&P) segment.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.